PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake

Hamideh Parhiz(University of Pennsylvania), Vladimir V. Shuvaev(University of Pennsylvania), Norbert Pardi(University of Pennsylvania), Makan Khoshnejad(University of Pennsylvania), Raisa Y. Kiseleva(University of Pennsylvania), Jacob S. Brenner(University of Pennsylvania), Thomas Uhler(University of Pennsylvania), Steven Tuyishime(University of Pennsylvania), Barbara L. Mui(Acuitas Therapeutics (Canada)), Ying K. Tam(Acuitas Therapeutics (Canada)), Thomas D. Madden(Acuitas Therapeutics (Canada)), Michael J. Hope(Acuitas Therapeutics (Canada)), Drew Weissman(University of Pennsylvania), Vladimir R. Muzykantov(University of Pennsylvania)
Journal of Controlled Release
October 15, 2018
10.1016/j.jconrel.2018.10.015
Cited by 224

Abstract

Related Papers

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Katalin Karikó, Michael Buckstein, Houping Ni et al.|Immunity|2005|2.6k
mRNA-based therapeutics — developing a new class of drugs
Uğur Şahin, Katalin Karikó, Özlem Türeci|Nature Reviews Drug Discovery|2014|2.4k
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Karikó, Hiromi Muramatsu, Frank A. Welsh et al.|Molecular Therapy|2008|1.8k
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
Norbert Pardi, Steven Tuyishime, Hiromi Muramatsu et al.|Journal of Controlled Release|2015|1k
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier, Muthusamy Jayaraman, Shigeo Matsuda et al.|Molecular Therapy|2013|615